Compound ID | 2239
F365
Synonym(s): QPX9003
Class: Lipopeptide
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Pseudomonas aeruginosa and Acinetobacter baumannii |
| Description: | Synthetic compound; rationally-designed derivative of polymyxin; reduced nephrotoxicity |
| Institute where first reported: | Qpex Biopharma, Inc.; Brii Biosciences; Monash University |
| Year first mentioned: | 2022 |
| Highest developmental phase: | Phase 1 (NCT04808414) |
| Development status: | Active (as of 2023) |
| External links: | |
| Citation: | https://www.nature.com/articles/s41467-022-29234-3 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.